What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?

Name: What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?
Uploaded: 2020-06-09T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine